文献速递外周动脉疾病

药物涂层球囊治疗通常被临床试验排除的股腘动脉病变:IN.PACT全球研究12个月结果

Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study.
PubMed 文献 · J Endovasc Ther · 2018-10-03

IN.PACT全球研究的事后分析将1406例受试者按IN.PACT SFA随机对照试验的入选/排除标准 retrospectively 分为标准使用组(n=281)和更广泛使用组(n=1125),评估12个月免于临床驱动的靶病变血运重建(CD-TLR)等终点。结果显示更广泛使用组病变更长、钙化更多且累及腘动脉、双侧病变及支架内再狭窄更多(所有p<0.001),12个月免于CD-TLR标准使用组96.6% vs 更广泛使用组91.6%(p=0.005),安全性终点96.2% vs 91.0%(p=0.003)。结论认为真实世界复杂病变患者12个月内临床改善持续一致。

要点

  • 更广泛使用组12个月免于CD-TLR为91.6%,标准使用组为96.6%(p=0.005)。
  • 更广泛使用组12个月CD-TLR为8.5%,标准使用组为3.4%(p=0.004)。
  • 12个月全因死亡率两组无显著差异(标准使用组3.8% vs 更广泛使用组3.4%,p=0.852)。

核心结论

  • IN.PACT全球研究真实世界患者的事后分析显示,通常被随机对照试验排除的复杂病变受试者在12个月内临床改善持续一致。

研究设计与样本

  • IN.PACT全球研究(ClinicalTrials.gov标识NCT01609296)纳入的1406例受试者被回顾性分配,依据IN.PACT SFA随机对照试验的入选和排除标准分为标准使用组(n=281)和更广泛使用组(n=1125)。
  • 评估12个月免于临床驱动的靶病变血运重建(CD-TLR),复合主要安全性终点为免于30天器械和操作相关死亡加上免于12个月靶肢体大截肢和临床驱动的靶血管血运重建(CD-TVR),功能结局采用专用问卷评估。

主要发现

  • 与标准使用组相比,更广泛使用组病变更长、钙化更多,且腘动脉受累、双侧病变和支架内再狭窄更多(所有p<0.001)。
  • Kaplan-Meier分析12个月免于CD-TLR标准使用组为96.6%,更广泛使用组为91.6%(p=0.005)。
  • 安全性终点标准使用组为96.2%,更广泛使用组为91.0%(p=0.003)。
  • 12个月CD-TLR标准使用组为3.4%,更广泛使用组为8.5%(p=0.004);CD-TVR标准使用组为4.2%,更广泛使用组为9.1%(p=0.008)。
  • 12个月全因死亡率未增加(标准使用组3.8% vs 更广泛使用组3.4%,p=0.852)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a post hoc analysis comparing outcomes between subjects who would have been included in the IN.PACT SFA randomized controlled trial vs those who would have been excluded. METHODS: The 1406 subjects enrolled in the IN.PACT Global Study ( ClinicalTrials.gov identifier NCT01609296) were retrospectively assigned to a standard-use group (n=281) based on the inclusion and exclusion criteria from the randomized IN.PACT SFA trial; the remaining 1125 patients were assigned to the broader-use group. Freedom from clinically-driven target lesion revascularization (CD-TLR) was evaluated at 12 months. The composite primary safety endpoint was freedom from 30-day device- and procedure-related death plus freedom from 12-month target limb major amputation and clinically-driven target vessel revascularization (CD-TVR). Functional outcomes were evaluated with dedicated questionnaires. RESULTS: Compared with the standard-use cohort, the broader-use lesions were longer, more calcified, and had more popliteal involvement, bilateral disease, and in-stent restenosis (p<0.001 for all). Freedom from 12-month CD-TLR by Kaplan-Meier analysis was 96.6% for the standard-use group and 91.6% for the broader-use group (p=0.005). The safety endpoint was 96.2% in the standard-use group and 91.0% in the broader-use group (p=0.003). The 12-month CD-TLR (3.4% standard-use vs 8.5% broader-use, p=0.004) and CD-TVR (4.2% standard-use vs 9.1% broader-use, p=0.008) were increased in the broader-use group. Twelve-month all-cause mortality was not increased (3.8% standard-use vs 3.4% broader-use, p=0.852). CONCLUSION: Post hoc analysis of the IN.PACT Global Study of real-world patients demonstrated consistent outcomes with significant clinical improvement to 12 months in subjects with complex lesions typically excluded from a randomized controlled trial.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Ansel GM, Brodmann M, Keirse K, et al. Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study. J Endovasc Ther. 2018. PMID: 30280648. doi:10.1177/1526602818803119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。